

## UNITED STATE PARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS (Washington, D.C. 20231

***************************************	į.
	ı
	ATTORNEY DOCKET NO

		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
APPLICATION NO.	FILING DATE	FIRST NAMED INVERTOR	

09/242,202

11/01/99


NELSON

E

2026-4236US1

HM22/0403

OFFICE OF TECHNOLOGY TRANSFER PATENT BRANCH NATIONAL INSTITUTES OF HEALTH 6011 EXECUTIVE BOULEVARD SUITE 325 ROCKVILLE MD 20852



Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 



UNITED STEES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

		•	
	<del></del>	FIRST NAMED APPLIC	ANT ATTORNEY DOCKET NO.
SERIAL NUMBER	FILING DATE		2026-4236US1
09/242,202	11/01/99	Nelson et al.	

EXAMINER			
Carrie Stroup			
ART UNIT	PAPER NUMBER		
1633	7		

## Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner Carrie Stroup, Art Unit 1633, whose telephone number is (703) 306-5439.

Any inquiry of a general nature or relating to the status of this application sould be directed to the Technology Center receptionist whose telephone number is (703)308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

JOHN L LEGUYADER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600



NUCLEOTIDE SEQUENCE AND/OR AWING AGID SEQUENCE DISSESSIVES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the

following reason(s):	
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	ļ
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide:	
Applicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its en	try
I'N into the specification.	
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For questions regarding compliance to these requirements, please contact:	
- But a Interpretation Call (703) 308-4216	
For CRF Submission Help, Call (705) 505 12 12	
Patentin Software Program Support (511-51)	
Technical Assistance703-306-2600  To Purchase Patentln Software703-306-2600	
TOTAL PROPONCE	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE